ABO21009 / AbolerIS Pharma - LARVOL DELTA

AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis (GlobeNewswire) - "The ongoing Phase 1 study is a first-in-human, adaptive design, randomized, single-blind, placebo-controlled dose escalation study with single ascending dosing in healthy volunteers (part I), single ascending dosing in patients with RA (part II) and multiple ascending dosing in patients with RA (part III) to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ABO21009....The Phase 1 study has been initiated in the Netherlands and is currently enrolling and dosing patients with RA under part II."

First-in-human • Trial status • Rheumatoid Arthritis

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis (PRNewswire) - "AbolerIS Pharma...announced today that the first cohort of participants has been dosed with ABO21009, a humanized anti-CD45RC monoclonal antibody, in a first-in-human Phase 1 study for the treatment of Rheumatoid Arthritis (RA)....In part I, 24 patients are planned to be enrolled who will receive one of four single doses of ABO21009 and will be followed up for up to 10 weeks; the Phase 1 study has been initiated in the Netherlands, and is currently enrolling and dosing participants."

Trial status • Rheumatoid Arthritis